Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intarcia

Gilead Sciences

Sovaldi pushes Gilead to the top of US pharma list

Blockbuster hep c pill sees the firm go from fourteenth to first in just one year

- PMLiVE

Merck appoints head of combined life science business

Udit Batra is CEO and president of Merck Millipore

- PMLiVE

Novo Nordisk opens insulin facility in Russia

It will focus on new modern insulin formulation and filling

- PMLiVE

Pfizer and Merck flesh out Xalkori alliance details

First stage of building a combined oncology sales organisation

- PMLiVE

Going the distance

Sanofi’s Pascale Witz on driving through change

- PMLiVE

FDA starts review of Novo’s refiled diabetes pair

Tresiba and Ryzodeg were rejected in 2013

- PMLiVE

PD-1 cancer market overrated, says new report

The immuno-oncology market for new oncology drugs may be worth half of current expectations

- PMLiVE

Merck adds another immuno-oncology tie-up

Firm to test Keytruda with Syndax’s entinostat in melanoma and NSCLC

- PMLiVE

Novo Nordisk will refile rejected diabetes duo in US

Danish firm hopes it will be second time lucky with key treatment

It’s time to get diabetes right

Patients should have access to the right treatment and care, at the right time, says the ABPI Pharmaceutical Diabetes Initiative 

- PMLiVE

Takeda’s once-weekly DPP-4 inhibitor cleared in first market

Zafatek’s authorisation one of a flurry of new approvals for a number of firms in Japan

- PMLiVE

AZ links with Harvard for diabetes research

Firm extends ties with the highly respected academic institution in hope of finding innovative leads

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links